Q1 Earnings Forecast for MacroGenics Issued By HC Wainwright

MacroGenics, Inc. (NASDAQ:MGNX) – Equities researchers at HC Wainwright raised their Q1 2025 EPS estimates for shares of MacroGenics in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst R. Burns now forecasts that the biopharmaceutical company will earn ($0.69) per share for the quarter, up from their previous forecast of ($0.70). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for MacroGenics’ current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for MacroGenics’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.89) EPS.

Separately, StockNews.com downgraded MacroGenics from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Nine analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, MacroGenics currently has a consensus rating of “Hold” and a consensus price target of $7.38.

MacroGenics Stock Performance

NASDAQ MGNX opened at $1.26 on Thursday. The business’s fifty day moving average is $2.51 and its 200 day moving average is $3.16. MacroGenics has a fifty-two week low of $1.26 and a fifty-two week high of $19.54. The company has a market capitalization of $79.49 million, a PE ratio of -0.80 and a beta of 2.12.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $49.40 million for the quarter, compared to analysts’ expectations of $34.17 million. MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MGNX. Wasatch Advisors LP raised its position in shares of MacroGenics by 37.6% during the fourth quarter. Wasatch Advisors LP now owns 3,488,493 shares of the biopharmaceutical company’s stock valued at $11,338,000 after buying an additional 952,691 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in MacroGenics during the fourth quarter valued at $2,787,000. JPMorgan Chase & Co. increased its holdings in MacroGenics by 68.3% in the 4th quarter. JPMorgan Chase & Co. now owns 546,807 shares of the biopharmaceutical company’s stock valued at $1,777,000 after acquiring an additional 221,905 shares during the last quarter. Renaissance Technologies LLC lifted its stake in MacroGenics by 69.1% in the 4th quarter. Renaissance Technologies LLC now owns 538,523 shares of the biopharmaceutical company’s stock worth $1,750,000 after purchasing an additional 220,100 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of MacroGenics by 5.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,175,665 shares of the biopharmaceutical company’s stock valued at $10,321,000 after purchasing an additional 164,938 shares during the last quarter. 96.89% of the stock is currently owned by institutional investors.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.